Real-world data from 24 UK centres for the use of nintedanib for progressive fibrosing interstitial lung disease

Dixon, Giles, Hague, Samuel and Mulholland, Sarah , et al. (2023) Real-world data from 24 UK centres for the use of nintedanib for progressive fibrosing interstitial lung disease. European Respiratory Journal, 62 (suppl 67). (doi:10.1183/13993003.congress-2023.PA404).

Abstract

Background: nintedanib was approved in the UK for use in progressive fibrosing interstitial lung disease (PF-ILD) in November 2021. The prescribing criteria defines PF-ILD using the diagnostic criteria established by the INBUILD study. There has been no national evaluation of the use of nintedanib for PF-ILD in a real-world setting.

Methods: a service evaluation was distributed to specialist interstitial lung disease (ILD) centres in the UK in September 2022. Local clinical audit department approval was obtained.

Results: 24 centres responded to the service evaluation invitation. Between 17/11/2021 and 30/09/2022, 1120 patients were commenced on nintedanib for PF-ILD. The most common diagnoses were hypersensitivity pneumonitis (298/1120,26.6%), connective tissue disease ILD (197/1120,17.6%), rheumatoid arthritis associated ILD disease (180/1120,16.0%), idiopathic non-specific interstitial pneumonia (125/1120,11.1%) and unclassifiable idiopathic interstitial pneumonic (100/1120,8.9%). Figure 1 demonstrates dual use of immunosupression and anti-fibrotic therapy.

Discussion: this real-world service evaluation demonstrates widespread use in the UK of nintedanib for a broad range of PF-ILD subtypes. Contrary to the INBUILD study, clinicians are commonly using combined immunomodulatory and anti-fibrotic therapy.

This record has no associated files available for download.

Contributors

Download statistics